$OTLC
Oncotelic Therapeutics, Inc.

2013 Q4 Form 10-Q Financial Statement

#000119312513438876 Filed on November 13, 2013

View on sec.gov

Income Statement

Concept 2013 Q4 2013 Q3 2012 Q3
Revenue $0.00 $95.00K $0.00
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $980.0K $1.580M $1.220M
YoY Change 4.26% 29.51% -6.87%
% of Gross Profit
Research & Development $1.120M $1.165M $1.015M
YoY Change 45.45% 14.78% -7.73%
% of Gross Profit
Depreciation & Amortization $30.00K $20.00K $20.00K
YoY Change -40.0% 0.0% -33.33%
% of Gross Profit
Operating Expenses $2.100M $2.742M $2.239M
YoY Change 22.81% 22.47% -6.71%
Operating Profit -$2.647M -$2.239M
YoY Change 18.22%
Interest Expense $0.00 $0.00 $0.00
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net $0.00 $0.00 -$10.00K
YoY Change -100.0% -100.0%
Pretax Income -$2.100M -$2.650M -$2.250M
YoY Change 25.0% 17.78% -35.9%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$2.100M -$2.646M -$2.247M
YoY Change 25.0% 17.76% -35.98%
Net Earnings / Revenue -2785.26%
Basic Earnings Per Share
Diluted Earnings Per Share -$0.48 -$1.88 -$1.51
COMMON SHARES
Basic Shares Outstanding 3.134M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2013 Q4 2013 Q3 2012 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $7.010M $8.780M $6.300M
YoY Change 41.62% 39.37% -50.16%
Cash & Equivalents $7.010M $8.780M $6.300M
Short-Term Investments
Other Short-Term Assets $67.00K $129.0K $330.0K
YoY Change -52.82% -60.91% 13.79%
Inventory
Prepaid Expenses $93.00K $172.0K
Receivables
Other Receivables
Total Short-Term Assets $7.165M $9.098M $6.630M
YoY Change 36.66% 37.22% -48.72%
LONG-TERM ASSETS
Property, Plant & Equipment $36.00K $5.000K $20.00K
YoY Change 176.92% -75.0% -50.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00
YoY Change -100.0%
Total Long-Term Assets $129.0K $123.0K $240.0K
YoY Change -36.76% -48.75% -46.67%
TOTAL ASSETS
Total Short-Term Assets $7.165M $9.098M $6.630M
Total Long-Term Assets $129.0K $123.0K $240.0K
Total Assets $7.294M $9.221M $6.870M
YoY Change 33.91% 34.22% -48.65%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $476.0K $733.0K $510.0K
YoY Change 14.42% 43.73% 8.51%
Accrued Expenses $780.0K $780.0K $740.0K
YoY Change 59.18% 5.41% -70.4%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.251M $1.515M $1.250M
YoY Change 38.85% 21.2% -57.91%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.251M $1.515M $1.250M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $1.250M $1.520M $1.250M
YoY Change 38.89% 21.6% -58.05%
SHAREHOLDERS EQUITY
Retained Earnings -$238.5M -$236.4M
YoY Change 5.8%
Common Stock $244.6M $244.1M
YoY Change 6.34%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $6.043M $7.706M $5.620M
YoY Change
Total Liabilities & Shareholders Equity $7.294M $9.221M $6.870M
YoY Change 33.91% 34.22% -48.65%

Cashflow Statement

Concept 2013 Q4 2013 Q3 2012 Q3
OPERATING ACTIVITIES
Net Income -$2.100M -$2.646M -$2.247M
YoY Change 25.0% 17.76% -35.98%
Depreciation, Depletion And Amortization $30.00K $20.00K $20.00K
YoY Change -40.0% 0.0% -33.33%
Cash From Operating Activities -$2.130M -$1.530M -$2.170M
YoY Change 13.3% -29.49% -11.07%
INVESTING ACTIVITIES
Capital Expenditures $40.00K
YoY Change 300.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$40.00K
YoY Change 300.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 400.0K 2.570M 1.570M
YoY Change -24.53% 63.69% -76.28%
NET CHANGE
Cash From Operating Activities -2.130M -1.530M -2.170M
Cash From Investing Activities -40.00K
Cash From Financing Activities 400.0K 2.570M 1.570M
Net Change In Cash -1.770M 1.040M -600.0K
YoY Change 30.15% -273.33% -114.35%
FREE CASH FLOW
Cash From Operating Activities -$2.130M -$1.530M -$2.170M
Capital Expenditures $40.00K
Free Cash Flow -$2.170M
YoY Change 14.81%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2013Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
70000000 shares
CY2013Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
3134092 shares
CY2013Q2 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
1377412 shares
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
119000 shares
CY2013Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
2452431 shares
CY2013Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2012Q3 us-gaap Cash
Cash
6303000
CY2013Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
2.80
CY2013Q3 oxgn Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights Related Party
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRelatedParty
147145 shares
CY2013Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2999000 shares
CY2013Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2999000 shares
CY2013Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
6000 shares
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
12.19
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
205000 shares
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
13.09
CY2013Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
5313000 shares
CY2013Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
15000000 shares
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
169000 shares
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
15.18
CY2013Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
70000000 shares
CY2013Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2013Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2013Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
6000 shares
CY2013Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
2.24
CY2013Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2013Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
360000
CY2013Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
580000
CY2013Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
733000
CY2013Q3 us-gaap Liabilities Current
LiabilitiesCurrent
1515000
CY2013Q3 us-gaap Stockholders Equity
StockholdersEquity
7706000
CY2013Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
244087000
CY2013Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
0
CY2013Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-236411000
CY2013Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1382000
CY2013Q3 us-gaap Common Stock Value
CommonStockValue
30000
CY2013Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
9221000
CY2013Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q3 us-gaap Assets Current
AssetsCurrent
9098000
CY2013Q3 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
20000
CY2013Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
172000
CY2013Q3 us-gaap Assets
Assets
9221000
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
CY2013Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
365000
CY2013Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
118000
CY2013Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
CY2013Q3 us-gaap Other Assets Current
OtherAssetsCurrent
129000
CY2013Q3 us-gaap Cash
Cash
8777000
CY2013Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
116988
CY2013Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5000
CY2013Q3 oxgn Accrued Research And Development
AccruedResearchAndDevelopment
202000
CY2013Q3 oxgn Cash Restricted Cash And Cash Equivalents
CashRestrictedCashAndCashEquivalents
8797000
CY2013Q3 oxgn Threshold Limit Percentage On Warrants Owned
ThresholdLimitPercentageOnWarrantsOwned
0.0999 pure
CY2011Q4 us-gaap Cash
Cash
9972000
CY2012Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1746000 shares
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1746000 shares
CY2012Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
19.73
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
143000 shares
CY2012Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
13000 shares
CY2012Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
15000000 shares
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
70000000 shares
CY2012Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2012Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2012Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2012Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2012Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
357000
CY2012Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
304000
CY2012Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
416000
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
901000
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
4546000
CY2012Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
229961000
CY2012Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
0
CY2012Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-225432000
CY2012Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1309000
CY2012Q4 us-gaap Common Stock Value
CommonStockValue
17000
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5447000
CY2012Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2012Q4 us-gaap Assets Current
AssetsCurrent
5243000
CY2012Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
20000
CY2012Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
135000
CY2012Q4 us-gaap Assets
Assets
5447000
CY2012Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
370000
CY2012Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
191000
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
CY2012Q4 us-gaap Other Assets Current
OtherAssetsCurrent
142000
CY2012Q4 us-gaap Cash
Cash
4946000
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13000
CY2012Q4 oxgn Accrued Research And Development
AccruedResearchAndDevelopment
181000
CY2013Q3 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
5800000
CY2013Q3 oxgn Classes Of Warrants Or Right Term Exercise Period
ClassesOfWarrantsOrRightTermExercisePeriod
P5Y
dei Entity Registrant Name
EntityRegistrantName
OXIGENE INC
dei Amendment Flag
AmendmentFlag
false
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2013-09-30
dei Entity Central Index Key
EntityCentralIndexKey
0000908259
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P7Y11D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0095 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.00 pure
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y4M17D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P4Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2268000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.90
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000 pure
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4871000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.84
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
107000 shares
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y6M26D
us-gaap Lease Expiration Date1
LeaseExpirationDate1
2014-06-30
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
45000 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y2M1D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
16.48
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> <i>Use of Estimates</i></p> <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> The preparation of financial statements in conformity with U.S.&#xA0;generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Actual results could differ from those estimates.</p> </div>
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
24000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6180000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10979000
us-gaap Investment Income Interest
InvestmentIncomeInterest
3000
us-gaap Operating Income Loss
OperatingIncomeLoss
-6183000
us-gaap Net Income Loss
NetIncomeLoss
-6180000
us-gaap Sales Revenue Net
SalesRevenueNet
95000
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
6334000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
614000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3764000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8702000
us-gaap Cost Of Goods Sold
CostOfGoodsSold
0
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
2198000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
432000
us-gaap Adjustment For Amortization
AdjustmentForAmortization
73000
us-gaap Share Based Compensation
ShareBasedCompensation
638000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
3831000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1936000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
5000000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2514000
us-gaap Depreciation
Depreciation
8000
us-gaap Operating Expenses
OperatingExpenses
6278000
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
4799000
oxgn Non Cash Deemed Preferred Stock Dividend
NonCashDeemedPreferredStockDividend
4799000
oxgn Class Of Warrant Or Right Term
ClassOfWarrantOrRightTerm
P5Y
oxgn Adjusted Base Monthly Rent Under Facility Lease
AdjustedBaseMonthlyRentUnderFacilityLease
16616.25
oxgn Area Of Facility Lease
AreaOfFacilityLease
5275 sqft
oxgn Classes Of Warrants Or Right Term Exercise Period
ClassesOfWarrantsOrRightTermExercisePeriod
P5Y
oxgn Due Date From Which Monthly Base Rent Payable
DueDateFromWhichMonthlyBaseRentPayable
2013-07-01
oxgn Due Date To Which Monthly Base Rent Payable
DueDateToWhichMonthlyBaseRentPayable
2014-06-30
oxgn Inspection Period For Product Defects
InspectionPeriodForProductDefects
P30D
oxgn Percentage Of Distribution Revenue On Gross Margin Earned
PercentageOfDistributionRevenueOnGrossMarginEarned
0.20 pure
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1390000 shares
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6463000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.56
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-434000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6404000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6404000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-18000
us-gaap Investment Income Interest
InvestmentIncomeInterest
10000
us-gaap Operating Income Loss
OperatingIncomeLoss
-6401000
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
5000
us-gaap Net Income Loss
NetIncomeLoss
-6404000
us-gaap Sales Revenue Net
SalesRevenueNet
114000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1003000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3751000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2794000
us-gaap Adjustment For Amortization
AdjustmentForAmortization
74000
us-gaap Share Based Compensation
ShareBasedCompensation
429000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-3669000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2794000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2749000
us-gaap Restructuring Charges
RestructuringCharges
15000
us-gaap Depreciation
Depreciation
12000
us-gaap Operating Expenses
OperatingExpenses
6515000
CY2012Q4 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.083 pure
CY2012 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y7M21D
CY2012 oxgn Class Of Warrant Or Right Term
ClassOfWarrantOrRightTerm
P5Y
CY2012Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1485000 shares
CY2012Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.56
CY2012Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2247000
CY2012Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2247000
CY2012Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-10000
CY2012Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
2000
CY2012Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2239000
CY2012Q3 us-gaap Net Income Loss
NetIncomeLoss
-2247000
CY2012Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1220000
CY2012Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1015000
CY2012Q3 us-gaap Restructuring Charges
RestructuringCharges
4000
CY2012Q3 us-gaap Operating Expenses
OperatingExpenses
2239000
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
72993 shares
CY2013Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2640000 shares
CY2013Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.88
CY2013Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2646000
CY2013Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4964000
CY2013Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
1000
CY2013Q3 us-gaap Sales Revenue Net
SalesRevenueNet
95000
CY2013Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2647000
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
-2646000
CY2013Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1577000
CY2013Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1165000
CY2013Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
199913
CY2013Q3 us-gaap Operating Expenses
OperatingExpenses
2742000
CY2013Q3 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
2318000

Files In Submission

Name View Source Status
0001193125-13-438876-index-headers.html Edgar Link pending
0001193125-13-438876-index.html Edgar Link pending
0001193125-13-438876.txt Edgar Link pending
0001193125-13-438876-xbrl.zip Edgar Link pending
d599725d10q.htm Edgar Link pending
d599725dex311.htm Edgar Link pending
d599725dex312.htm Edgar Link pending
d599725dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
oxgn-20130930.xml Edgar Link completed
oxgn-20130930.xsd Edgar Link pending
oxgn-20130930_cal.xml Edgar Link unprocessable
oxgn-20130930_def.xml Edgar Link unprocessable
oxgn-20130930_lab.xml Edgar Link unprocessable
oxgn-20130930_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending